12:00 AM
Oct 12, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votrient pazopanib regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-0 that GlaxoSmithKline's Votrient pazopanib had a favorable risk-benefit profile for patients with renal cell carcinoma (RCC). ODAC based its...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >